Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
11.35 USD   +2.44%
11/29Alx Oncology Holdings Inc : Change in Directors or Principal Officers (form 8-K)
AQ
11/29Alx Oncology : Corporate Presentation
PU
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces the Selection of Evorpacept in the I-SPY-P1 Trial in Combination with Enhertu® in Breast Cancer

08/15/2022 | 07:00am EST

ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative announced that ALX Oncology's next generation CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. Sponsored by Quantum Leap, this Phase 1 (open-label), multi-center study arm will investigate evorpacept in combination with ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody-drug conjugate (“ADC”), to determine the safety, tolerability and efficacy of this drug combination. The I-SPY-P1 TRIAL will be led by Paula Pohlmann, Associate Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center.

ALX Oncology will provide funding and supply evorpacept. As the study sponsor, Quantum Leap will be responsible for managing the trial. The I-SPY TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis) was designed to rapidly screen promising experimental treatments and identify those most effective in specific patient subgroups based on molecular characteristics (biomarker signatures).

The trial is a unique collaborative effort by a consortium that includes the Food and Drug Administration (FDA), industry, patient advocates, philanthropic sponsors, and clinicians from 16 major U.S. cancer research centers. Under the terms of the collaboration agreement, Quantum Leap Healthcare Collaborative is the trial sponsor and manages all study operations.


© S&P Capital IQ 2022
All news about ALX ONCOLOGY HOLDINGS INC.
11/29Alx Oncology Holdings Inc : Change in Directors or Principal Officers (form 8-K)
AQ
11/29Alx Oncology : Corporate Presentation
PU
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
11/29ALX Oncology Appoints Scott Garland to its Board of Directors
GL
11/29ALX Oncology Holdings Inc. Appoints Scott Garland to Its Board of Directors
CI
11/09Transcript : ALX Oncology Holdings Inc. Presents at Credit Suisse 31st Annual..
CI
11/09HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains B..
MT
11/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
GL
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -131 M - -
Net cash 2022 255 M - -
P/E ratio 2022 -3,57x
Yield 2022 -
Capitalization 463 M 463 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 55
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 11,35 $
Average target price 35,00 $
Spread / Average Target 208%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-47.18%463
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.21.36%81 852
BIONTECH SE-34.16%41 250
WUXI APPTEC CO., LTD.-34.47%32 173
GENMAB A/S24.60%30 178